The fifth reorganization of Jilin Pharmacy failed again

In Saturday, the "reorganization of specialist" Jilin Pharmaceutical issued a notice that has not yet disclosed the plan for the fifth reorganization has been prematurely aborted, the stock will be a duplicate trading today. The announcement shows that since the February 25 suspension, Jilin pharmaceutical and related parties on major assets reorganization issues in-depth analysis, argumentation, and actively promote the work.　　However, due to the complexity of the matter, unable to complete the relevant work within the specified time, in order to safeguard the interests of investors, the company's shares will resume trading today, the company, the company's largest shareholder and the actual controller pledged to resume trading in the stock within 3 months will no longer plan major asset reorganization.　　In the first four disclosure of the reorganization plan and successively defeated, Jilin Pharmaceutical fifth reorganization slightly implicit, but the fifth reorganization also experienced dystocia after the defeat. Industry analysts believe that, from the 2010 performance forecasts, Jilin Pharmaceutical has been a loss for two consecutive years, was *st a few foregone conclusion. At present, in the short term restructuring again failed to be a foregone conclusion, after the return of the stock price or will suffer a fall crisis, advised investors cautious attention.